VC-backed Agile Therapeutics rolls out IPO

Agile Therapeutics has launched its IPO after pricing its over 9.16 million shares at $6 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “AGRX.” RBC Capital Markets and William Blair & Company are the lead underwriters. Based in Princeton, NJ, Agile Therapeutics develops prescription contraceptives. Its backers include Aisling Capital, Care Capital, Investor Growth Capital, ProQuest Investments, Kaiser Permanente Ventures and Novitas Capital.

Andreessen Horowitz leads Series B round for Omada Health

Digital therapeutics firm Omada Health said Wednesday that it has raised $23 million in Series B financing. Andreessen Horowitz led the round with participation from Kaiser Permanente Ventures and previous backers that include U.S. Venture Partners and The Vertical Group. Also, Balaji S. Srinivasan, a general partner at Andreessen Horowitz, has been added to Omada Health’s board of directors.

114 Views

VC-backed Agile Therapeutics files for IPO

Agile Therapeutics has filed for an IPO. The number of shares that will be offered as well as the pricing terms of the stock have yet to be set. RBC Capital Markets and William Blair & Company will serve as the lead underwriters. Based in Princeton, NJ, Agile Therapeutics is a women’s health specialty pharmaceutical company focused on developing prescription contraceptives. Its backers include Aisling Capital, Care Capital, Investor Growth Capital, ProQuest Investments, Kaiser Permanente Ventures and Novitas Capital.

112 Views

VC-backed TriVascular files for IPO

TriVascular Technologies has filed for an IPO. The number of shares that will be offered as well as its pricing terms have yet to be set. The stock will trade on the NASDAQ under the ticker symbol “TRIV.” J.P. Morgan Securities and Credit Suisse Securities are the lead underwriters. Based in Santa Rosa, Calif., TriVascular Technologies is a provider of endovascular aortic repair solutions. Its backers include NEA, Delphi Ventures, MPM Capital, Kearny Venture Partners, Kaiser Permanente Ventures, Rock Springs Capital and Permal Asset Management.

Kaiser Permanente Ventures and CHV Capital Back Health Catalyst

Health Catalyst, a Salt Lake City-based data warehousing company that’s focused on healthcare, has added $8 million to its Series B round, care of Kaiser Permanente Ventures and CHV Capital. Previously, the company had raised $33 million for its Series B, from investors that include Norwest Venture Partners, Sequoia Capital and Sorenson Capital.

Valeritas Lands $150M Series C

Valeritas Inc., a Bridgewater, N.J.-based developer of drug delivery systems for the diabetes market, has raised $150 million in Series C financing. The funding will support commercialization of its V-Go disposable insulin delivery device. Welsh, Carson, Anderson & Stowe led the financing and assumes a controlling interest in Valeritas. Previous investors MPM Capital, Pitango Venture Capital, Abingworth Management, Advanced Technology Ventures, ONSET Ventures, HLM Venture Partners, Agate Medical Investments, CHL Medical Partners and Kaiser Permanente Ventures also participated.

Kaiser Permanente Ventures Adds LPs, Expands Team

Kaiser Permanente Ventures has added two new limited partners, bringing its current fund to $170 million, the firm announced. It has also expanded its team, adding Sam Brasch as a director and Yan Pu as an analyst. Brasch was most recently at Frazier Healthcare Ventures. Pu worked previously in life sciences and healthcare strategy consulting with IMS Health and Navigant Consulting. Kaiser Permanente Ventures invests in medical device, health care service, diagnostic and drug delivery.

Transcend Medical Sews Up $51M Series B

Transcend Medical Inc., a Menlo Park, Calif.-based ophthalmic device company, has closed a second tranche of its Series B round, bringing the total to an eye-popping $51 million. Investors include Investor Growth Capital, Canaan Partners, Finistere Ventures, HLM Venture Partners, Kaiser Permanente Ventures, Latterell Venture Partners, Morgenthaler Ventures, Split Rock Partners and Technology Partners. The company says it will use the funds to develop additional infrastructure and resources for a U.S. study of its micro-stent technology. The company is focused on minimally invasive glaucoma therapies.

Will the Frosty Reception for AcelRX Put Other IPOs on Ice?

Life can be hard for young biotechs, but that doesn’t mean the market is sympathetic.  AcelRX Pharmaceuticals of Redwood City, Calif., is the latest biotech to receive a cold reception from investors. After slashing its planned offering price from between $12 and $14 to $5 per share, the stock has been trending downward since its debut […]

Arcxis Secures Series B

Arcxis Biotechnologies, a privately held biomedical device firm, announced today that it has completed the first close of its Series B round. Claremont Creek Ventures, who led the round, was joined by Kaiser Permanente Ventures and Alafi Capital. These funds will enable Arcxis to accelerate development, testing, and commercialization of their innovative nucleic acid sample […]

PEHUB Community

Join the 12503 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget